

# CITATION REPORT

List of articles citing

## Viagra or what?

DOI: [10.1038/sj.eye.6700697](https://doi.org/10.1038/sj.eye.6700697)

Eye, 2004, 18, 446-8.

**Source:** <https://exaly.com/paper-pdf/36813779/citation-report.pdf>

**Version:** 2022-09-30

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 751-8	1	14
10	Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 12-27	1	55
9	Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?. <i>British Journal of Ophthalmology</i> , <b>2007</b> , 91, 1551-5	5.3	26
8	Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 262, 89-97	1.4	23
7	Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?. <i>Current Urology Reports</i> , <b>2007</b> , 8, 482-90	2.8	6
6	Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 537-43	2.1	16
5	Nonarteritic anterior ischaemic optic neuropathy. <i>Current Opinion in Ophthalmology</i> , <b>2008</b> , 19, 461-7	5	12
4	Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. <i>Drug Safety</i> , <b>2009</b> , 32, 1-18	4.9	55
3	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 650-61	7.8	130
2	Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use. <i>Journal of Neuro-Ophthalmology</i> , <b>2016</b> , 36, 480-481	2.4	3
1	Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review. <i>Journal of Ophthalmic and Vision Research</i> , <b>2021</b> , 16, 248-259	1.1	0